Benzinga | Jan 18, 2022 01:02PM EST

This Is What Whales Are Betting On BioNTech

A whale with a lot of money to spend has taken a noticeably bearish stance on BioNTech.

Looking at options history for BioNTech (NASDAQ:BNTX) we detected 14 strange trades.

If we consider the specifics of each trade, it is accurate to state that 28% of the investors opened trades with bullish expectations and 71% with bearish.

From the overall spotted trades, 11 are puts, for a total amount of $859,002 and 3, calls, for a total amount of $83,460.

What's The Price Target?

Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $150.0 to $400.0 for BioNTech over the last 3 months.

Volume & Open Interest Development

Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for BioNTech's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of BioNTech's whale trades within a strike price range from $150.0 to $400.0 in the last 30 days.

BioNTech Option Volume And Open Interest Over Last 30 Days

Biggest Options Spotted:

Symbol PUT/ Trade Sentiment Exp. Strike Total Trade Open Volume CALL Type Date Price Price InterestBNTX PUT SWEEP BEARISH 03/18/ $195.00 $224.2K 307 103 22BNTX PUT SWEEP BEARISH 01/21/ $350.00 $178.0K 115 12 22BNTX PUT SWEEP BEARISH 03/18/ $195.00 $110.3K 307 103 22BNTX PUT SWEEP BULLISH 01/21/ $180.00 $79.2K 1.6K 232 22BNTX PUT TRADE BEARISH 09/16/ $200.00 $50.0K 67 10 22

Where Is BioNTech Standing Right Now?

* With a volume of 2,673,470, the price of BNTX is down -12.73% at $171.05.

* RSI indicators hint that the underlying stock may be oversold.

* Next earnings are expected to be released in 70 days.

What The Experts Say On BioNTech:

* HC Wainwright & Co. has decided to maintain their Buy rating on BioNTech, which currently sits at a price target of $366.

* Morgan Stanley has decided to maintain their Equal-Weight rating on BioNTech, which currently sits at a price target of $284.

Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.

If you are already an options trader or would like to get started, head on over to Benzinga Pro. Benzinga Pro gives you up-to-date news and analytics to empower your investing and trading strategy.